Opella — Sanofi’s consumer healthcare unit — launched its Act Your Age campaign for pain relief cream Aspercreme last month. The marketing effort puts a new spin on the concept of aging by elevating ...

Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT ...

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Wall Street losses accelerated on Friday, with investors closing out the week with gloomy economic updates and report of a government investigation into UnitedHealth (UNH) in hand. However, the S ...

Given that the film is being released on the first day of spring, the allergy relief brand from Opella saw an opportunity for some cheeky medical marketing. In the spot, the aptly named Sneezy is seen ...

South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...

In a response to the US SEC decision Sanofi neither admitted nor denied any wrongdoing, but confirmed it will pay $25.2 million and agreed to a two-year period of self-reporting on effectiveness ...

Sanofi Consumer Healthcare India Ltd share price was down by -0.48% from the previous closing price of ₹4,799.50. Who are peers of Sanofi Consumer Healthcare India Ltd? The peers of Sanofi ...